{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:28:36Z","timestamp":1793489316205,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Type 2\n                    <jats:sup>high<\/jats:sup>\n                    asthma, which accounts for the majority of asthma cases, is driven by Th2 cells that produce cytokines such as IL-4, IL-5, and IL-13. These cytokines promote several features of the disease, including eosinophilia, IgE production, bronchial hyperresponsiveness (BHR), mucus hypersecretion, and susceptibility to exacerbations. In contrast, type 2\n                    <jats:sup>low<\/jats:sup>\n                    asthma is characterized by the presence of neutrophils and reduced responsiveness to corticosteroids. In recent years, advances in our understanding of the distinct mechanisms at play in each asthma endotype have paved the way for the development of targeted therapies tailored to specific patient profiles. In this review, we first explore the underlying immunological mechanisms of various asthma endotypes. We also provide an overview of the different types of immunotherapies currently available to asthmatic patients and their clinical efficacy. Finally, we\u00a0highlight emerging therapeutic strategies that hold promise for improving asthma management in the future.\n                  <\/jats:p>","DOI":"10.1038\/s41423-025-01357-9","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:34:49Z","timestamp":1761554089000},"page":"1521-1532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunotherapy for asthma"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-8603","authenticated-orcid":false,"given":"Hamida","family":"Hammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N.","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1357_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD Diseases","year":"2020","unstructured":"Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u201322.","journal-title":"Lancet"},{"key":"1357_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41590-025-02212-9","volume":"26","author":"BN Lambrecht","year":"2025","unstructured":"Lambrecht BN, Ahmed E, Hammad H. The immunology of asthma. Nat Immunol. 2025;26:1233\u201345.","journal-title":"Nat Immunol"},{"key":"1357_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.anai.2023.03.001","volume":"130","author":"BE Chipps","year":"2023","unstructured":"Chipps BE, Soong W, Panettieri RA Jr, Carr W, Gandhi H, Zhou W, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130:784\u201390 e5.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1357_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1164\/rccm.201808-1543OC","volume":"199","author":"W Wu","year":"2019","unstructured":"Wu W, Bang S, Bleecker ER, Castro M, Denlinger L, Erzurum SC, et al. Multiview cluster analysis identifies variable corticosteroid response phenotypes in severe asthma. Am J Respir Crit Care Med. 2019;199:1358\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"1357_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-042220-015902","volume":"18","author":"H Aegerter","year":"2023","unstructured":"Aegerter H, Lambrecht BN. The pathology of asthma: what is obstructing our view?. Annu Rev Pathol. 2023;18:387\u2013409.","journal-title":"Annu Rev Pathol"},{"key":"1357_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaip.2025.01.010","volume":"13","author":"J Gotschke","year":"2025","unstructured":"Gotschke J, Walter J, Leuschner G, Gerckens M, Gotschke M, Mertsch P, et al. Mucus Plug score predicts clinical and pulmonary function response to biologic therapy in patients with severe asthma. J Allergy Clin Immunol Pr. 2025;13:1110\u201322 e1.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1357_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","volume":"127","author":"J Lotvall","year":"2011","unstructured":"Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. 2015;15:57\u201365.","journal-title":"Nat Rev Immunol"},{"key":"1357_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht BN, Hammad H, Fahy JV. The Cytokines of asthma. Immunity. 2019;50:975\u201391.","journal-title":"Immunity"},{"key":"1357_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1164\/rccm.201807-1291OC","volume":"199","author":"MC Peters","year":"2019","unstructured":"Peters MC, Ringel L, Dyjack N, Herrin R, Woodruff PG, Rios C, et al. A transcriptomic method to determine airway immune dysfunction in T2-High and T2-low asthma. Am J Respir Crit Care Med. 2019;199:465\u201377.","journal-title":"Am J Respir Crit Care Med"},{"key":"1357_CR11","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.jaip.2024.06.010","volume":"12","author":"NG Papadopoulos","year":"2024","unstructured":"Papadopoulos NG, Bacharier LB, Jackson DJ, Deschildre A, Phipatanakul W, Szefler SJ, et al. Type 2 inflammation and asthma in children: a narrative review. J Allergy Clin Immunol Pr. 2024;12:2310\u201324.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1357_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1771","volume":"14","author":"NZ Kermani","year":"2024","unstructured":"Kermani NZ, Li CX, Versi A, Badi Y, Sun K, Abdel-Aziz MI, et al. Endotypes of severe neutrophilic and eosinophilic asthma from multiomics integration of U-BIOPRED sputum samples. Clin Transl Med. 2024;14:e1771.","journal-title":"Clin Transl Med"},{"key":"1357_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jaci.2020.05.039","volume":"147","author":"JW Steinke","year":"2021","unstructured":"Steinke JW, Lawrence MG, Teague WG, Braciale TJ, Patrie JT, Borish L. Bronchoalveolar lavage cytokine patterns in children with severe neutrophilic and paucigranulocytic asthma. J Allergy Clin Immunol. 2021;147:686\u201393 e3.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1164\/rccm.202402-0403OC","volume":"211","author":"JV Fahy","year":"2025","unstructured":"Fahy JV, Jackson ND, Sajuthi SP, Pruesse E, Moore CM, Everman JL, et al. Type 1 Immune responses related to viral infection influence corticosteroid response in asthma. Am J Respir Crit Care Med. 2025;211:194\u2013204.","journal-title":"Am J Respir Crit Care Med"},{"key":"1357_CR15","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1172\/JCI80911","volume":"125","author":"M Raundhal","year":"2015","unstructured":"Raundhal M, Morse C, Khare A, Oriss TB, Milosevic J, Trudeau J, et al. High IFN-gamma and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125:3037\u201350.","journal-title":"J Clin Invest"},{"key":"1357_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/CM9.0000000000002456","volume":"136","author":"Y Feng","year":"2023","unstructured":"Feng Y, Liu X, Wang Y, Du R, Mao H. Delineating asthma according to inflammation phenotypes with a focus on paucigranulocytic asthma. Chin Med J (Engl). 2023;136:1513\u201322.","journal-title":"Chin Med J (Engl)"},{"key":"1357_CR17","doi-asserted-by":"crossref","unstructured":"Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. & Group UBS. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49:1602135.","DOI":"10.1183\/13993003.02135-2016"},{"key":"1357_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2500\/aap.2021.42.210060","volume":"42","author":"M Olgac","year":"2021","unstructured":"Olgac M, Guler SD, Demir S, Unal D, Ertek B, Ozseker ZF, et al. Paucigranulocytic asthma: Do sputum macrophages matter?. Allergy Asthma Proc. 2021;42:530\u201336.","journal-title":"Allergy Asthma Proc"},{"key":"1357_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/cea.13609","volume":"50","author":"M Fricker","year":"2020","unstructured":"Fricker M, Qin L, Niessen N, Baines KJ, McDonald VM, Scott HA, et al. Relationship of sputum mast cells with clinical and inflammatory characteristics of asthma. Clin Exp Allergy. 2020;50:696\u2013707.","journal-title":"Clin Exp Allergy"},{"key":"1357_CR20","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2021","unstructured":"Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184:1469\u201385.","journal-title":"Cell"},{"key":"1357_CR21","doi-asserted-by":"crossref","unstructured":"Camacho DF, Velez TE, Hollinger MK, Wang E, Howard CL, Darnell EP, et al. IRF4 expression by lung dendritic cells drives acute but not Trm cell-dependent memory Th2 responses. JCI Insight 2022;7:e140384.","DOI":"10.1172\/jci.insight.140384"},{"key":"1357_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.it.2023.04.004","volume":"44","author":"B Leon","year":"2023","unstructured":"Leon B. A model of Th2 differentiation based on polarizing cytokine repression. Trends Immunol. 2023;44:399\u2013407.","journal-title":"Trends Immunol"},{"key":"1357_CR23","doi-asserted-by":"crossref","unstructured":"Lyons-Cohen MR, Shamskhou EA, Gerner MY. Site-specific regulation of Th2 differentiation within lymph node microenvironments. J Exp Med 2024;221:e20231282.","DOI":"10.1084\/jem.20231282"},{"key":"1357_CR24","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41590-024-02007-4","volume":"25","author":"H Nagashima","year":"2024","unstructured":"Nagashima H, Shayne J, Jiang K, Petermann F, Pekowska A, Kanno Y, et al. Remodeling of Il4-Il13-Il5 locus underlies selective gene expression. Nat Immunol. 2024;25:2220\u201333.","journal-title":"Nat Immunol"},{"key":"1357_CR25","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","volume":"125","author":"KD Stone","year":"2010","unstructured":"Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125:S73\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR26","doi-asserted-by":"crossref","unstructured":"Harker JA, Lloyd CM. T helper 2 cells in asthma. J Exp Med 2023;220:e20221094.","DOI":"10.1084\/jem.20221094"},{"key":"1357_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mucimm.2024.10.003","volume":"18","author":"F Bick","year":"2025","unstructured":"Bick F, Blanchetot C, Lambrecht BN, Schuijs MJ. A reappraisal of IL-9 in inflammation and cancer. Mucosal Immunol. 2025;18:1\u201315.","journal-title":"Mucosal Immunol"},{"key":"1357_CR28","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jaci.2024.07.024","volume":"154","author":"F Bick","year":"2024","unstructured":"Bick F, Brenis Gomez CM, Lammens I, Van Moorleghem J, De Wolf C, DuPont S, et al. IL-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma. J Allergy Clin Immunol. 2024;154:1129\u201345.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","volume":"136","author":"S Sehra","year":"2015","unstructured":"Sehra S, Yao W, Nguyen ET, Glosson-Byers NL, Akhtar N, Zhou B, et al. TH9 cells are required for tissue mast cell accumulation during allergic inflammation. J Allergy Clin Immunol. 2015;136:433\u201340 e1.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR30","doi-asserted-by":"crossref","unstructured":"Schmitt P, Duval A, Camus M, Lefrancais E, Roga S, Dedieu C, et al. TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation. J Exp Med 2024;221:e20231236.","DOI":"10.1084\/jem.20231236"},{"key":"1357_CR31","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1164\/rccm.201810-1869OC","volume":"199","author":"ME Lachowicz-Scroggins","year":"2019","unstructured":"Lachowicz-Scroggins ME, Dunican EM, Charbit AR, Raymond W, Looney MR, Peters MC, et al. Extracellular DNA, neutrophil extracellular traps, and inflammasome activation in severe asthma. Am J Respir Crit Care Med. 2019;199:1076\u201385.","journal-title":"Am J Respir Crit Care Med"},{"key":"1357_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2009.02.024","volume":"123","author":"W Al-Ramli","year":"2009","unstructured":"Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Lemiere C, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123:1185\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR33","doi-asserted-by":"crossref","unstructured":"Gauthier M, Chakraborty K, Oriss TB, Raundhal M, Das S, Chen J, et al. Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias. JCI Insight 2017;2:e94580.","DOI":"10.1172\/jci.insight.94580"},{"key":"1357_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3743048","volume":"2017","author":"H Gao","year":"2017","unstructured":"Gao H, Ying S, Dai Y. Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target. J Immunol Res. 2017;2017:3743048.","journal-title":"J Immunol Res"},{"key":"1357_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","volume":"39","author":"J Tanaka","year":"2009","unstructured":"Tanaka J, Watanabe N, Kido M, Saga K, Akamatsu T, Nishio A, et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy. 2009;39:89\u2013100.","journal-title":"Clin Exp Allergy"},{"key":"1357_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nm.4332","volume":"23","author":"M Toussaint","year":"2017","unstructured":"Toussaint M, Jackson DJ, Swieboda D, Guedan A, Tsourouktsoglou TD, Ching YM, et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med. 2017;23:681\u201391.","journal-title":"Nat Med"},{"key":"1357_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70011","volume":"330","author":"M Gauthier","year":"2025","unstructured":"Gauthier M, Kale SL, Ray A. T1-T2 interplay in the complex immune landscape of severe asthma. Immunol Rev. 2025;330:e70011.","journal-title":"Immunol Rev"},{"key":"1357_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(54)91620-7","volume":"266","author":"AW Frankland","year":"1954","unstructured":"Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet. 1954;266:1055\u20137.","journal-title":"Lancet"},{"key":"1357_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/0091-6749(78)90116-1","volume":"61","author":"PS Norman","year":"1978","unstructured":"Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol. 1978;61:370\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2500\/aap.2020.41.200035","volume":"41","author":"A Bozek","year":"2020","unstructured":"Bozek A, Cudak A, Walter Canonica G. Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis. Allergy Asthma Proc. 2020;41:271\u201377.","journal-title":"Allergy Asthma Proc"},{"key":"1357_CR41","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJM199908123410702","volume":"341","author":"SR Durham","year":"1999","unstructured":"Durham SR, Walker SM, Varga EM, Jacobson MR, O\u2019Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468\u201375.","journal-title":"N Engl J Med"},{"key":"1357_CR42","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/all.13208","volume":"72","author":"S Dhami","year":"2017","unstructured":"Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017;72:1825\u201348.","journal-title":"Allergy"},{"key":"1357_CR43","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jaci.2003.12.586","volume":"113","author":"P Maestrelli","year":"2004","unstructured":"Maestrelli P, Zanolla L, Pozzan M, Fabbri LM, Regione Veneto Study Group on the \u201cEffect of immunotherapy in allergic a. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004;113:643\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR44","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.5415\/apallergy.2021.11.e32","volume":"11","author":"T Uchida","year":"2021","unstructured":"Uchida T, Nakagome K, Iemura H, Naito E, Miyauchi S, Uchida Y, et al. Clinical evaluation of rush immunotherapy using house dust mite allergen in Japanese asthmatics. Asia Pac Allergy. 2021;11:e32.","journal-title":"Asia Pac Allergy"},{"key":"1357_CR45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/ACI.0000000000000853","volume":"22","author":"TEG Epstein","year":"2022","unstructured":"Epstein TEG, Calabria CW. Is immunotherapy safe for treatment of severe asthma. Curr Opin Allergy Clin Immunol. 2022;22:396\u2013401.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1357_CR46","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1016\/j.jaip.2019.06.003","volume":"7","author":"M Hoshino","year":"2019","unstructured":"Hoshino M, Akitsu K, Kubota K. Effect of sublingual immunotherapy on airway inflammation and airway wall thickness in allergic asthma. J Allergy Clin Immunol Pr. 2019;7:2804\u201311.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1357_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaci.2014.03.019","volume":"134","author":"H Mosbech","year":"2014","unstructured":"Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134:568\u201375 e7.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jaip.2019.09.002","volume":"8","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Tohda Y, Okamiya K, Azuma R, Terada I, Adachi M. Efficacy and safety of HDM SLIT tablet in japanese adults with allergic asthma. J Allergy Clin Immunol Pr. 2020;8:710\u201320 e14.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1357_CR49","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1001\/jama.2016.3964","volume":"315","author":"JC Virchow","year":"2016","unstructured":"Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315:1715\u201325.","journal-title":"JAMA"},{"key":"1357_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.arbres.2019.06.001","volume":"56","author":"JL Lopez-Campos","year":"2020","unstructured":"Lopez-Campos JL, Soler-Cataluna JJ, Miravitlles M. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. Arch Bronconeumol. 2020;56:65\u201367.","journal-title":"Arch Bronconeumol"},{"key":"1357_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100206","volume":"3","author":"M Hoshino","year":"2024","unstructured":"Hoshino M, Akitsu K, Ohtawa J, Kubota K. Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis. J Allergy Clin Immunol Glob. 2024;3:100206.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"1357_CR52","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/all.14264","volume":"76","author":"JM Schmid","year":"2021","unstructured":"Schmid JM, Wurtzen PA, Siddhuraj P, Jogdand P, Petersen CG, Dahl R, et al. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. Allergy. 2021;76:1528\u201338.","journal-title":"Allergy"},{"key":"1357_CR53","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.4049\/jimmunol.172.5.3252","volume":"172","author":"KT Nouri-Aria","year":"2004","unstructured":"Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252\u20139.","journal-title":"J Immunol"},{"key":"1357_CR54","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.jaci.2008.03.013","volume":"121","author":"S Radulovic","year":"2008","unstructured":"Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121:1467\u201372, 72 e1.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR55","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.mucimm.2024.03.012","volume":"17","author":"K Van der Borght","year":"2024","unstructured":"Van der Borght K, Brimnes J, Haspeslagh E, Brand S, Neyt K, Gupta S, et al. Sublingual allergen immunotherapy prevents house dust mite inhalant type 2 immunity through dendritic cell-mediated induction of Foxp3(+) regulatory T cells. Mucosal Immunol. 2024;17:618\u201332.","journal-title":"Mucosal Immunol"},{"key":"1357_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000536335","volume":"185","author":"L Martin-Cruz","year":"2024","unstructured":"Martin-Cruz L, Benito-Villalvilla C, Sirvent S, Angelina A, Palomares O. The role of regulatory T cells in allergic diseases: Collegium Internationale Allergologicum (CIA) Update 2024. Int Arch Allergy Immunol. 2024;185:503\u201318.","journal-title":"Int Arch Allergy Immunol"},{"key":"1357_CR57","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.4049\/jimmunol.178.7.4658","volume":"178","author":"C Pilette","year":"2007","unstructured":"Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol. 2007;178:4658\u201366.","journal-title":"J Immunol"},{"key":"1357_CR58","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2013.01.014","volume":"131","author":"W van de Veen","year":"2013","unstructured":"van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Sollner S, Akdis DG, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131:1204\u201312.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR59","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/all.14908","volume":"76","author":"MH Shamji","year":"2021","unstructured":"Shamji MH, Valenta R, Jardetzky T, Verhasselt V, Durham SR, Wurtzen PA, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy. 2021;76:3627\u201341.","journal-title":"Allergy"},{"key":"1357_CR60","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.immuni.2020.12.013","volume":"54","author":"K Golebski","year":"2021","unstructured":"Golebski K, Layhadi JA, Sahiner U, Steveling-Klein EH, Lenormand MM, Li RCY, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021;54:291\u2013307 e7.","journal-title":"Immunity"},{"key":"1357_CR61","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.jaci.2018.12.1018","volume":"143","author":"H Morita","year":"2019","unstructured":"Morita H, Kubo T, Ruckert B, Ravindran A, Soyka MB, Rinaldi AO, et al. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J Allergy Clin Immunol. 2019;143:2190\u2013201 e9.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR62","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.jaci.2020.08.042","volume":"147","author":"A Eljaszewicz","year":"2021","unstructured":"Eljaszewicz A, Ruchti F, Radzikowska U, Globinska A, Boonpiyathad T, Gschwend A, et al. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy. J Allergy Clin Immunol. 2021;147:1865\u201377.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1084\/jem.20040035","volume":"200","author":"HJ de Heer","year":"2004","unstructured":"de Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, Willart MA, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med. 2004;200:89\u201398.","journal-title":"J Exp Med"},{"key":"1357_CR64","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.4049\/jimmunol.0900471","volume":"183","author":"M Kool","year":"2009","unstructured":"Kool M, van Nimwegen M, Willart MA, Muskens F, Boon L, Smit JJ, et al. An anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflammation. J Immunol. 2009;183:1074\u201382.","journal-title":"J Immunol"},{"key":"1357_CR65","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/cea.12308","volume":"44","author":"C Shen","year":"2014","unstructured":"Shen C, Hupin C, Froidure A, Detry B, Pilette C. Impaired ICOSL in human myeloid dendritic cells promotes Th2 responses in patients with allergic rhinitis and asthma. Clin Exp Allergy. 2014;44:831\u201341.","journal-title":"Clin Exp Allergy"},{"key":"1357_CR66","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/cmi.2017.26","volume":"15","author":"CM Wang","year":"2018","unstructured":"Wang CM, Chang CB, Chan MW, Wen ZH, Wu SF. Dust mite allergen-specific immunotherapy increases IL4 DNA methylation and induces Der p-specific T-cell tolerance in children with allergic asthma. Cell Mol Immunol. 2018;15:963\u201372.","journal-title":"Cell Mol Immunol"},{"key":"1357_CR67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jaci.2021.06.012","volume":"149","author":"C Benito-Villalvilla","year":"2022","unstructured":"Benito-Villalvilla C, Perez-Diego M, Angelina A, Kisand K, Rebane A, Subiza JL, et al. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. J Allergy Clin Immunol. 2022;149:212\u201322 e9.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/all.16387","volume":"80","author":"R Mosges","year":"2025","unstructured":"Mosges R, Raskopf E, Klimek L, Pfaar O, Zielen S, Xenofontos E, et al. Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy. Allergy. 2025;80:817\u201326.","journal-title":"Allergy"},{"key":"1357_CR69","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/all.15910","volume":"79","author":"R Mosges","year":"2024","unstructured":"Mosges R, Zeyen C, Raskopf E, Acikel C, Sahin H, Allekotte S, et al. A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids. Allergy. 2024;79:990\u20131000.","journal-title":"Allergy"},{"key":"1357_CR70","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1111\/all.15374","volume":"77","author":"A Nieto","year":"2022","unstructured":"Nieto A, Mazon A, Nieto M, Ibanez E, Jang DT, Calaforra S, et al. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. Allergy. 2022;77:3096\u2013107.","journal-title":"Allergy"},{"key":"1357_CR71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309\u201316.","journal-title":"Allergy"},{"key":"1357_CR72","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","volume":"34","author":"ST Holgate","year":"2004","unstructured":"Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632\u20138.","journal-title":"Clin Exp Allergy"},{"key":"1357_CR73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","volume":"7","author":"TB Casale","year":"2019","unstructured":"Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: Evidence From PROSPERO, A prospective real-world study. J Allergy Clin Immunol Pr. 2019;7:156\u201364 e1.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1357_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1033511","volume":"10","author":"G Fenu","year":"2022","unstructured":"Fenu G, La Tessa A, Calogero C, Lombardi E. Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile. Front Pediatr. 2022;10:1033511.","journal-title":"Front Pediatr"},{"key":"1357_CR75","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.4049\/jimmunol.175.9.5724","volume":"175","author":"JT Schroeder","year":"2005","unstructured":"Schroeder JT, Bieneman AP, Xiao H, Chichester KL, Vasagar K, Saini S, et al. TLR9- and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by downregulating receptor expression. J Immunol. 2005;175:5724\u201331.","journal-title":"J Immunol"},{"key":"1357_CR76","doi-asserted-by":"crossref","unstructured":"Lopez-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3(+)Tregs. Eur Respir J 2021;57:2000751.","DOI":"10.1183\/13993003.00751-2020"},{"key":"1357_CR77","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/all.15567","volume":"78","author":"C Benito-Villalvilla","year":"2023","unstructured":"Benito-Villalvilla C, de la Rocha-Munoz A, Lopez-Abente J, Eggel A, Bottoli I, Severin T, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-alpha production and FOXP3(+) Treg generation. Allergy. 2023;78:1060\u201372.","journal-title":"Allergy"},{"key":"1357_CR78","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","volume":"141","author":"MA Gill","year":"2018","unstructured":"Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141:1735\u201343 e9.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR79","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1111\/all.15385","volume":"77","author":"S Carraro","year":"2022","unstructured":"Carraro S, di Palmo E, Licari A, Barni S, Caldarelli V, De Castro G, et al. Asthma N. Metabolomics to identify omalizumab responders among children with severe asthma: a prospective study. Allergy. 2022;77:2852\u20136.","journal-title":"Allergy"},{"key":"1357_CR80","doi-asserted-by":"crossref","unstructured":"Humbert M, Taille C, Mala L, Le Gros V, Just J, Molimard M, investigators S. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 2018;51:1702523.","DOI":"10.1183\/13993003.02523-2017"},{"key":"1357_CR81","first-page":"286","volume":"103","author":"K Narasimhan","year":"2021","unstructured":"Narasimhan K. Difficult to Treat and severe asthma: management strategies. Am Fam Physician. 2021;103:286\u201390.","journal-title":"Am Fam Physician"},{"key":"1357_CR82","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386:157\u201371.","journal-title":"N Engl J Med"},{"key":"1357_CR83","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1172\/JCI19133","volume":"113","author":"JY Cho","year":"2004","unstructured":"Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest. 2004;113:551\u201360.","journal-title":"J Clin Invest"},{"key":"1357_CR84","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","volume":"142","author":"M Godar","year":"2018","unstructured":"Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol. 2018;142:1185\u201393 e4.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR85","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med"},{"key":"1357_CR86","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"1357_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105806","volume":"159","author":"FC Albers","year":"2019","unstructured":"Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806.","journal-title":"Respir Med"},{"key":"1357_CR88","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","volume":"33","author":"M Goldman","year":"2017","unstructured":"Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33:1605\u201313.","journal-title":"Curr Med Res Opin"},{"key":"1357_CR89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","volume":"164","author":"MJ McIntosh","year":"2023","unstructured":"McIntosh MJ, Kooner HK, Eddy RL, Wilson A, Serajeddini H, Bhalla A, et al. CT Mucus Score and (129)Xe MRI Ventilation Defects After 2.5 Years\u2019 Anti-IL-5Ralpha in Eosinophilic Asthma. Chest. 2023;164:27\u201338.","journal-title":"Chest"},{"key":"1357_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","volume":"13","author":"A Shackleford","year":"2025","unstructured":"Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025;13:23\u201334.","journal-title":"Lancet Respir Med"},{"key":"1357_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150162","volume":"14","author":"I Pavord","year":"2023","unstructured":"Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Front Immunol. 2023;14:1150162.","journal-title":"Front Immunol"},{"key":"1357_CR92","doi-asserted-by":"crossref","unstructured":"Pini L, Bagnasco D, Beghe B, Braido F, Cameli P, Caminati M, et al. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. J Clin Med 2024;13:3013.","DOI":"10.3390\/jcm13103013"},{"key":"1357_CR93","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaci.2022.10.028","volume":"151","author":"R Chan","year":"2023","unstructured":"Chan R, RuiWen Kuo C, Jabbal S, Lipworth BJ. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma. J Allergy Clin Immunol. 2023;151:700\u201305 e10.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR94","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/all.16425","volume":"80","author":"MB Soendergaard","year":"2025","unstructured":"Soendergaard MB, Hansen S, Hakansson KEJ, von Bulow A, Bjerrum AS, Schmid JM, et al. Early reduction of FeNO on anti-IL5 biologics is associated with clinical remission of severe asthma. Allergy. 2025;80:986\u201395.","journal-title":"Allergy"},{"key":"1357_CR95","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"Jackson","year":"2024","unstructured":"Jackson, Wechsler DJ, Jackson ME, Bernstein DJ, Korn D, Pfeffer S, et al. Twice-yearly Depemokimab in severe asthma with an Eosinophilic phenotype. N Engl J Med. 2024;391:2337\u201349.","journal-title":"N Engl J Med"},{"key":"1357_CR96","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4161\/mabs.1.3.8352","volume":"1","author":"AA Long","year":"2009","unstructured":"Long AA. Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs. 2009;1:237\u201346.","journal-title":"MAbs"},{"key":"1357_CR97","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1067\/mai.2001.115624","volume":"107","author":"LC Borish","year":"2001","unstructured":"Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963\u201370.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR98","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nm.2754","volume":"18","author":"CA Akdis","year":"2012","unstructured":"Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012;18:736\u201349.","journal-title":"Nat Med"},{"key":"1357_CR99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bcp.12589","volume":"80","author":"F Hua","year":"2015","unstructured":"Hua F, Ribbing J, Reinisch W, Cataldi F, Martin S. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Br J Clin Pharm. 2015;80:101\u20139.","journal-title":"Br J Clin Pharm"},{"key":"1357_CR100","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","volume":"365","author":"J Corren","year":"2011","unstructured":"Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088\u201398.","journal-title":"N Engl J Med"},{"key":"1357_CR101","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomized placebo-controlled studies. Thorax. 2015;70:748\u201356.","journal-title":"Thorax"},{"key":"1357_CR102","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","volume":"12","author":"J Corren","year":"2024","unstructured":"Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, et al. Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined Type 2 population. J Allergy Clin Immunol Pr. 2024;12:1215\u201324 e3.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1357_CR103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/JAA.S69932","volume":"8","author":"DJ Maselli","year":"2015","unstructured":"Maselli DJ, Keyt H, Rogers L. Profile of lebrikizumab and its potential in the treatment of asthma. J Asthma Allergy. 2015;8:87\u201392.","journal-title":"J Asthma Allergy"},{"key":"1357_CR104","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","volume":"3","author":"CE Brightling","year":"2015","unstructured":"Brightling CE, Chanez P, Leigh R, O\u2019Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomized, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692\u2013701.","journal-title":"Lancet Respir Med"},{"key":"1357_CR105","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455\u201366.","journal-title":"N Engl J Med"},{"key":"1357_CR106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomized double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31\u201344.","journal-title":"Lancet"},{"key":"1357_CR107","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"1357_CR108","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.anai.2018.08.005","volume":"122","author":"J Corren","year":"2019","unstructured":"Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122:41\u201349 e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1357_CR109","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.anai.2019.04.028","volume":"123","author":"J Corren","year":"2019","unstructured":"Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, et al. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 2019;123:222\u201324 e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1357_CR110","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of Dupilumab in Glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475\u201385.","journal-title":"N Engl J Med"},{"key":"1357_CR111","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","volume":"385","author":"LB Bacharier","year":"2021","unstructured":"Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021;385:2230\u201340.","journal-title":"N Engl J Med"},{"key":"1357_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107535","volume":"224","author":"A Papi","year":"2024","unstructured":"Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, et al. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma. Respir Med. 2024;224:107535.","journal-title":"Respir Med"},{"key":"1357_CR113","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","volume":"208","author":"S Svenningsen","year":"2023","unstructured":"Svenningsen S, Kjarsgaard M, Haider E, Venegas C, Konyer N, Friedlander Y, et al. Effects of Dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2023;208:995\u201397.","journal-title":"Am J Respir Crit Care Med"},{"key":"1357_CR114","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.alit.2024.02.002","volume":"73","author":"T Tajiri","year":"2024","unstructured":"Tajiri T, Suzuki M, Nishiyama H, Ozawa Y, Kurokawa R, Takeda N, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergol Int. 2024;73:406\u201315.","journal-title":"Allergol Int"},{"key":"1357_CR115","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","volume":"13","author":"M Castro","year":"2025","unstructured":"Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, Gonzalez-Barcala FJ, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomized, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208\u201320.","journal-title":"Lancet Respir Med"},{"key":"1357_CR116","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","volume":"3","author":"C Moussion","year":"2008","unstructured":"Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019?. PLoS One. 2008;3:e3331.","journal-title":"PLoS One"},{"key":"1357_CR117","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16:676\u201389.","journal-title":"Nat Rev Immunol"},{"key":"1357_CR118","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.4049\/jimmunol.0802387","volume":"183","author":"D Prefontaine","year":"2009","unstructured":"Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183:5094\u2013103.","journal-title":"J Immunol"},{"key":"1357_CR119","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nm.1946","volume":"15","author":"H Hammad","year":"2009","unstructured":"Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. 2009;15:410\u20136.","journal-title":"Nat Med"},{"key":"1357_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21589-2","volume":"8","author":"IC Scott","year":"2018","unstructured":"Scott IC, Majithiya JB, Sanden C, Thornton P, Sanders PN, Moore T, et al. Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage. Sci Rep. 2018;8:3363.","journal-title":"Sci Rep"},{"key":"1357_CR121","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2019.08.039","volume":"144","author":"J Allinne","year":"2019","unstructured":"Allinne J, Scott G, Lim WK, Birchard D, Erjefalt JS, Sanden C, et al. IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol. 2019;144:1624\u201337 e10.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR122","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.4049\/jimmunol.1600611","volume":"197","author":"LK Johnston","year":"2016","unstructured":"Johnston LK, Hsu CL, Krier-Burris RA, Chhiba KD, Chien KB, McKenzie A, et al. IL-33 precedes IL-5 in regulating Eosinophil commitment and is required for Eosinophil Homeostasis. J Immunol. 2016;197:3445\u201353.","journal-title":"J Immunol"},{"key":"1357_CR123","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3389\/fimmu.2019.01361","volume":"10","author":"E Ronnberg","year":"2019","unstructured":"Ronnberg E, Ghaib A, Ceriol C, Enoksson M, Arock M, Safholm J, et al. Divergent effects of acute and prolonged Interleukin 33 exposure on mast cell IgE-mediated functions. Front Immunol. 2019;10:1361.","journal-title":"Front Immunol"},{"key":"1357_CR124","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, et al. Efficacy and safety of Itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385:1656\u201368.","journal-title":"N Engl J Med"},{"key":"1357_CR125","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021;148:790\u201398.","journal-title":"J Allergy Clin Immunol"},{"key":"1357_CR126","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1172\/JCI124606","volume":"129","author":"F Roan","year":"2019","unstructured":"Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest. 2019;129:1441\u201351.","journal-title":"J Clin Invest"},{"key":"1357_CR127","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.4049\/jimmunol.178.3.1396","volume":"178","author":"M Omori","year":"2007","unstructured":"Omori M, Ziegler S. Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. J Immunol. 2007;178:1396\u2013404.","journal-title":"J Immunol"},{"key":"1357_CR128","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.immuni.2006.03.019","volume":"24","author":"YH Wang","year":"2006","unstructured":"Wang YH, Ito T, Wang YH, Homey B, Watanabe N, Martin R, et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity. 2006;24:827\u201338.","journal-title":"Immunity"},{"key":"1357_CR129","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/j.1398-9995.2012.02868.x","volume":"67","author":"M Morshed","year":"2012","unstructured":"Morshed M, Yousefi S, Stockle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67:1127\u201337.","journal-title":"Allergy"},{"key":"1357_CR130","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1365-2222.2011.03919.x","volume":"42","author":"NS Redhu","year":"2012","unstructured":"Redhu NS, Gounni AS. Function and mechanisms of TSLP\/TSLPR complex in asthma and COPD. Clin Exp Allergy. 2012;42:994\u20131005.","journal-title":"Clin Exp Allergy"},{"key":"1357_CR131","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","volume":"181","author":"S Ying","year":"2008","unstructured":"Ying S, O\u2019Connor B, Ratoff J, Meng Q, Fang C, Cousins D, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181:2790\u20138.","journal-title":"J Immunol"},{"key":"1357_CR132","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","volume":"174","author":"S Ying","year":"2005","unstructured":"Ying S, O\u2019Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174:8183\u201390.","journal-title":"J Immunol"},{"key":"1357_CR133","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","volume":"9","author":"S Diver","year":"2021","unstructured":"Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. and investigators Cs. Effect of tezepelumab on airway inflammatory cells, remodeling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomized, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:1299\u2013312.","journal-title":"Lancet Respir Med"},{"key":"1357_CR134","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12931-020-01513-x","volume":"21","author":"C Emson","year":"2020","unstructured":"Emson C, Diver S, Chachi L, Megally A, Small C, Downie J, et al. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. Respir Res. 2020;21:265.","journal-title":"Respir Res"},{"key":"1357_CR135","doi-asserted-by":"publisher","first-page":"EVIDoa2300135","DOI":"10.1056\/EVIDoa2300135","volume":"2","author":"LH Nordenmark","year":"2023","unstructured":"Nordenmark LH, Hellqvist A, Emson C, Diver S, Porsbjerg C, Griffiths JM, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2:EVIDoa2300135.","journal-title":"NEJM Evid"},{"key":"1357_CR136","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128:997\u20131009.","journal-title":"J Clin Invest"},{"key":"1357_CR137","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.anai.2024.09.016","volume":"134","author":"L Seluk","year":"2025","unstructured":"Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025;134:9\u201318.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1357_CR138","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","volume":"188","author":"WW Busse","year":"2013","unstructured":"Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294\u2013302.","journal-title":"Am J Respir Crit Care Med"},{"key":"1357_CR139","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomized, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4:797\u2013806.","journal-title":"Lancet Respir Med"},{"key":"1357_CR140","doi-asserted-by":"crossref","unstructured":"Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, et al. Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond. Eur Respir J 2023;61:2202202.","DOI":"10.1183\/13993003.02202-2022"},{"key":"1357_CR141","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936\u201346.","journal-title":"N Engl J Med"},{"key":"1357_CR142","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.arbres.2023.05.014","volume":"59","author":"BG Cosio","year":"2023","unstructured":"Cosio BG, Shafiek H, Iglesias A, Mosteiro M, Gonzalez-Pineiro A, Rodriguez M, et al. Validation of a pathological score for the assessment of bronchial biopsies in severe uncontrolled asthma: beyond blood Eosinophils. Arch Bronconeumol. 2023;59:502\u201309.","journal-title":"Arch Bronconeumol"},{"key":"1357_CR143","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179\u201384.","journal-title":"Science"},{"key":"1357_CR144","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","volume":"8","author":"J Skuljec","year":"2017","unstructured":"Skuljec J, Chmielewski M, Happle C, Habener A, Busse M, Abken H, et al. Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma. Front Immunol. 2017;8:1125\u201336.","journal-title":"Front Immunol"},{"key":"1357_CR145","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41590-024-01834-9","volume":"25","author":"G Jin","year":"2024","unstructured":"Jin G, Liu Y, Wang L, He Z, Zhao X, Ma Y, et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nat Immunol. 2024;25:1059\u201372.","journal-title":"Nat Immunol"},{"key":"1357_CR146","doi-asserted-by":"publisher","first-page":"2004167","DOI":"10.1183\/13993003.04167-2020","volume":"56","author":"A Higham","year":"2020","unstructured":"Higham A, Leow-Dyke S, Jackson N, Singh D. Stability of eosinophilic inflammation in COPD bronchial biopsies. Eur Respir J. 2020;56:2004167.","journal-title":"Eur Respir J"},{"key":"1357_CR147","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024;390:2274\u201383.","journal-title":"N Engl J Med"},{"key":"1357_CR148","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomized, double-blind, phase 2a trial. Lancet Respir Med. 2021;9:1288\u201398.","journal-title":"Lancet Respir Med"},{"key":"1357_CR149","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/children12020167","volume":"12","author":"C Indolfi","year":"2025","unstructured":"Indolfi C, Klain A, Capuano MC, Colosimo S, Rapillo R, Miraglia Del Giudice M. Severe asthma in school-age children: an updated appraisal on biological options and challenges in this age group. Children. 2025;12:167.","journal-title":"Children"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01357-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T23:01:40Z","timestamp":1764457300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":149,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1038\/s41423-025-01357-9","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}